Lapiteronel

Overview

Lapiteronel (CFG920) is an orally active, nonsteroidal, reversible dual CYP17 and CYP11B2 inhibitor. Lapiteronel has the potential for metastatic castration-resistant prostate cancer research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-19833
• CAS No.: 1260006-20-9
• Molecular Formula: C14H13ClN4O
• Molecular Weight: 288.73
• Purity: 98.51%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (8.66 mM); Clear solution
• Availability: In-stock

Source

Original product source